Correvio Pharma (CORV) Tops Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Correvio Reports Fourth Quarter and Full Year 2018 Financial Results
March 13, 2019 7:00 AM EDTCompany on Track to Resubmit Brinavess NDA in Q2 2019
Mark H.N. Corrigan, MD to Commence CEO Duties on March 14, 2019
Management to Host Conference Call and Webcast Today, March 13, 2019 at 8:00 a.m. Eastern (5:00 a.m. Pacific)
NASDAQ: CORVÂ TSX: CORV
VANCOUVER, March 13, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its fourth quarter and year ended December 31, 2018 and commented on recent... More
